Bentiromide

Identification

Generic Name
Bentiromide
DrugBank Accession Number
DB00522
Background

Bentiromide is a dipeptide that is used in the bentiromide test, which is a screening test for evaluating pancreatic exocrine function and monitoring the adequacy of supplemental pancreatic therapy. It is typically administered orally. Cases of headache and gastrointestinal disturbances have been reported with the use of bentiromide. Bentiromide is currently not available in the U.S. or Canada.

Type
Small Molecule
Groups
Investigational, Withdrawn
Structure
Weight
Average: 404.4153
Monoisotopic: 404.13722176
Chemical Formula
C23H20N2O5
Synonyms
  • Bentiromide
  • Bentiromido
  • Bentiromidum
  • BTPABA
  • PFT
External IDs
  • E 2663
  • E-2663
  • Ro 11-7891

Pharmacology

Indication

Indicated as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Bentiromide is a peptide used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy. The amount of p-aminobenzoic acid and its metabolites excreted in the urine is the quantitative measure of the chymotrypsin-secreting activity of the pancreas.

Mechanism of action

Bentiromide is a peptide that is broken down in the pancreas by chymotrypsin. By determining the output of unchanged bentiromide in the urine following oral administration, it is possible to determine the sufficiency of pancreatic activity.

TargetActionsOrganism
ASerine protease hepsin
ligand
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Primarily hepatic. Enzymatic activity capable of hydrolyzing bentiromide has also been found in normal small intestine.

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Symptoms of overdose include shortness of breath and troubled breathing.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
PFD (Sannova)

Categories

ATC Codes
V04CK03 — Bentiromide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as tyrosine and derivatives. These are compounds containing tyrosine or a derivative thereof resulting from reaction of tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Tyrosine and derivatives
Alternative Parents
Phenylalanine and derivatives / Acylaminobenzoic acid and derivatives / Hippuric acids and derivatives / N-acyl-alpha amino acids and derivatives / Alpha amino acid amides / Amphetamines and derivatives / Anilides / Benzoic acids / N-arylamides / Benzoyl derivatives
show 9 more
Substituents
1-hydroxy-2-unsubstituted benzenoid / Acylaminobenzoic acid or derivatives / Alpha-amino acid amide / Amphetamine or derivatives / Anilide / Aromatic homomonocyclic compound / Benzamide / Benzenoid / Benzoic acid / Benzoic acid or derivatives
show 22 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
dipeptide (CHEBI:31263)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
239IF5W61J
CAS number
37106-97-1
InChI Key
SPPTWHFVYKCNNK-FQEVSTJZSA-N
InChI
InChI=1S/C23H20N2O5/c26-19-12-6-15(7-13-19)14-20(25-21(27)16-4-2-1-3-5-16)22(28)24-18-10-8-17(9-11-18)23(29)30/h1-13,20,26H,14H2,(H,24,28)(H,25,27)(H,29,30)/t20-/m0/s1
IUPAC Name
4-[(2S)-3-(4-hydroxyphenyl)-2-(phenylformamido)propanamido]benzoic acid
SMILES
OC(=O)C1=CC=C(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)C2=CC=CC=C2)C=C1

References

Synthesis Reference

DeBenneville, P.L.and Greenberger, N.J.; U.S. Patent 3,745,212; July 10,1973; assigned to Rohm & Haas Co.

General References
  1. Toskes PP: The bentiromide test for pancreatic exocrine insufficiency. Pharmacotherapy. 1984 Mar-Apr;4(2):74-80. [Article]
Human Metabolome Database
HMDB0014663
KEGG Drug
D01346
PubChem Compound
6957673
PubChem Substance
46508175
ChemSpider
5329364
BindingDB
50240073
RxNav
18896
ChEBI
31263
ChEMBL
CHEMBL1200368
ZINC
ZINC000000608204
PharmGKB
PA164750572
Wikipedia
Bentiromide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
  • Savage laboratories inc div altana inc
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)240-242DeBenneville, P.L.and Greenberger, N.J.; U.S. Patent 3,745,212; July 10,1973; assigned to Rohm & Haas Co.
logP3.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00412 mg/mLALOGPS
logP2.99ALOGPS
logP3.54Chemaxon
logS-5ALOGPS
pKa (Strongest Acidic)4.16Chemaxon
pKa (Strongest Basic)-1.3Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area115.73 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity112.74 m3·mol-1Chemaxon
Polarizability42.12 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.5224
Blood Brain Barrier+0.7085
Caco-2 permeable-0.7954
P-glycoprotein substrateNon-substrate0.5201
P-glycoprotein inhibitor INon-inhibitor0.9668
P-glycoprotein inhibitor IINon-inhibitor0.9765
Renal organic cation transporterNon-inhibitor0.9466
CYP450 2C9 substrateNon-substrate0.7866
CYP450 2D6 substrateNon-substrate0.8148
CYP450 3A4 substrateNon-substrate0.6344
CYP450 1A2 substrateNon-inhibitor0.8856
CYP450 2C9 inhibitorNon-inhibitor0.7744
CYP450 2D6 inhibitorNon-inhibitor0.9233
CYP450 2C19 inhibitorNon-inhibitor0.8775
CYP450 3A4 inhibitorNon-inhibitor0.9168
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9014
Ames testNon AMES toxic0.9317
CarcinogenicityNon-carcinogens0.8637
BiodegradationNot ready biodegradable0.7682
Rat acute toxicity1.8601 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9831
hERG inhibition (predictor II)Non-inhibitor0.9543
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0a4l-0951000000-3408813d239b684fcca1
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-0795800000-9c5bf5ad4184cdf857e4
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0uxu-0865900000-a4c67f3204b43285247e
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0bta-0930100000-1b073620bb47b5862d03
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0f8m-2790000000-202090311aeeb786f68b
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0kor-2910000000-e264f6d22d0a9022c18d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-01bc-5941000000-c0ea94056e3bcd17f3ef
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-208.8920146
predicted
DarkChem Lite v0.1.0
[M-H]-209.6462146
predicted
DarkChem Lite v0.1.0
[M-H]-193.92606
predicted
DeepCCS 1.0 (2019)
[M+H]+209.5849146
predicted
DarkChem Lite v0.1.0
[M+H]+210.4293146
predicted
DarkChem Lite v0.1.0
[M+H]+196.32161
predicted
DeepCCS 1.0 (2019)
[M+Na]+209.5085146
predicted
DarkChem Lite v0.1.0
[M+Na]+209.9071146
predicted
DarkChem Lite v0.1.0
[M+Na]+202.25203
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Ligand
General Function
Serine-type peptidase activity
Specific Function
Plays an essential role in cell growth and maintenance of cell morphology. May mediate the activating cleavage of HGF and MST1/HGFL. Plays a role in the proteolytic processing of ACE2.
Gene Name
HPN
Uniprot ID
P05981
Uniprot Name
Serine protease hepsin
Molecular Weight
45011.01 Da
References
  1. Chowdhury RS, Forsmark CE: Review article: Pancreatic function testing. Aliment Pharmacol Ther. 2003 Mar 15;17(6):733-50. [Article]
  2. Bujanover Y, Harel A, Geter R, Blau H, Yahav J, Spirer Z: The development of the chymotryptic activity during postnatal life using the bentiromide test. Int J Pancreatol. 1988 Jan-Feb;3(1):53-8. [Article]
  3. Toskes PP: The bentiromide test for pancreatic exocrine insufficiency. Pharmacotherapy. 1984 Mar-Apr;4(2):74-80. [Article]
  4. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Drug created at June 13, 2005 13:24 / Updated at March 03, 2024 02:27